

### Dyslipidemia in P

# EVAL

DATE: February 12, 2022 LOCATION: location name 117 silver linden dr, Silver Linden Dr.

ch Centre is cor us in evaluating nal offerings, plo	g the effectiven	ess of this p	rogram and to	make
☐ Other	Please specify_			
☐ Part-time	☐ Solo	☐ Group	☐ Office	□н
/, I am better ab	le to:			
to the 2021 CC	S Dyslipidemia	Guidelines f	or primary and	d secon
Disagree	Neutral		Agree	
2	3		4	
vho would bene	fit from additio	nal therapy k	peyond statins	to redu
Disagree	Neutral		Agree	
2	3		4	

new 2021 CCS Dyslipidemia Guideline recommendations into ro

#### was effective in presenting the material:

Strongly disagree	Disagree	
1	2	
Did you perceive any degree of bias in any part		
If Yes, please describe:		

## Please indicate which Caddressed during this e

ge

	Strongly agree
4	5

#### uestions

	Strongly agree
4	5

#### ality in health care

	Strongly	agree
4		5

#### evidence-based

	Strongly agree
4	5

### tive opportunities for active ussion, Q &A, etc)

	Strongly agree
4	5

#### eraction with my peers

Family Medicine Expert

Collaborator

Communicator

Manager

Health Advocate

Professional

Scholar

Strongly agree